Q3 Revenues and Gross Profit Continue Strong Trend

ST. JOHN’S, NL / ACCESSWIRE / August 31, 2015 / Bluedrop Performance Learning “Bluedrop” (TSX-V: BPL) today reported its financial results for the three months ended June 30, 2015.

Revenues for the three months ended June 30, 2015 were $5.4 million, up from $4.5 million, an increase of 18% on the same period in the previous year. Gross profit for the period was $2.3 million, an increase of $0.6 million over the three month period ended June 30, 2014. Pre-tax loss was $0.4 million for the three month period compared to a loss of $0.2 million in the same period in the previous year. After tax loss for the period was $0.4 million compared to after tax loss of $0.2 million for the same period in the previous year.

For the first nine month of the year revenues were $15.0 million, versus $11.0 million, an increase of 36% compared to the same period last year. Gross margins were $6.0 million, versus $4.1 million, an increase of $1.9 million versus the same period last year. Pre-tax income was a loss of $0.2 million, versus a loss of $3.7 million, a decrease of $3.5 million versus the same period last year. After tax loss for the period was $0.3 million compared to after tax loss of $2.8 million for the same period in the previous year.

Gross Profit for the quarter was the highest of any quarter yet reported by the Company and operating costs were in line with previous quarters but income was adversely effected in the quarter as the Company took a charge of $0.7 million related to the Scientific Research & Experimental Development (SR&ED) claims from prior periods. This had the effect of reducing income by $0.3 million in the quarter. No SR&ED credits have been accrued for this current fiscal year.

The Training and Simulation group entered into a 5 year agreement with The Boeing Corporation to develop the next generation crew trainer for the Chinook helicopter in July. Under this program Boeing will among other things, provide $2.3 million in cash contributions, provide engineering support, deliver specific intellectual property with respect to details of the Chinook helicopter, and provide global marketing support for the new product. The company expects to increase its levels of research and development spending with these funds.

For further details please see the Financial Statements and Management’s Discussion and Analysis for the quarter ended June 30, 2015 which are available on the Company’s web site at www.bluedrop.com or on SEDAR at www.sedar.com.

Commenting on the results and year to date progress of Bluedrop, Founder and CEO Emad Rizkalla said, “I am pleased with the continued growth in the Training and Simulation business, their consistent financial performance and a special congratulations to the team on the recently announced Boeing program. Learning Networks is presently very engaged in some large pursuits and delivering against some recent awards but as with our new SaaS model and the revenue recognition rules that apply it will take time to show up in the quarterly results. I was disappointed in the SR&ED charge but over the last few years it has been much more challenging to meet the criteria for software development under the program.”

About Bluedrop

Bluedrop Performance Learning (TSX-V: BPL) is an innovator in workplace training for individuals, corporations, military personnel and the public sector. Bluedrop is transforming the workplace by designing, developing and delivering practical, actionable and affordable training content that improves individual and overall performance of organizations.

For more information, visit www.bluedrop.com.

This news release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements, other than statements of historical fact included in this release, including, without limitation, statements regarding the impact of the operational restructuring and future plans and objectives of Bluedrop, constitute forward-looking information that involve various risks and uncertainties. Forward looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the operational efficiencies associated with the integration of technological and financial systems and general economic and market conditions. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information.

Important factors that could cause actual results to differ materially from Bluedrop’s expectations include general global economic conditions. For additional information with respect to risk factors applicable to Bluedrop, reference should be made to Bluedrop’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Bluedrop’s Management’s Discussion and Analysis of Results of Operations and Financial Condition For the Year Ended September 30, 2014. The forward-looking information contained in this release is made as of the date of this release and Bluedrop does not undertake to update publicly or revise the forward-looking information contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Media contact:

Lynn Hammond
Bluedrop Performance Learning Inc.
lynnhammond@bluedrop.com
709-570-5691
709-330-1260

SOURCE: Bluedrop Performance Learning Inc.

ReleaseID: 431640

NEW YORK, NY / ACCESSWIRE / August 31, 2015 / Aeterna Zentaris Inc. (NASDAQ: AEZS) shares took a bounce to $.085 on Friday from its low of $.08, after a fall from $.21 on July 21st. With the impending phase III results expected in early October the following due diligence may provide insight for current and potential shareholders.

View critical due diligence by using the link below at no cost.

http://bit.ly/_AEZS_Due_Diligence – Copy and paste to browser may be required.

About Aeterna Zentaris, Inc.:

Aeterna Zentaris engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.

About Broad Street Alerts:

We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement:

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure:

Content is researched, written and reviewed on a best-effort basis by a Michael McCord, Chartered Financial Analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

Contact:
editor@broadstreetalerts.com

SOURCE: Broad Street Alerts

ReleaseID: 431630

NEW YORK, NY / ACCESSWIRE / August 31, 2015 / The selloff in the energy sector lead by the collapse in oil prices has created tremendous opportunities for traders to profit, especially in periods of high volatility such as the past couple of weeks. We highlight four companies that traders can use to realize magnified returns relative to the move in oil and gas prices.

Shareholders of Basic Energy Services, Inc. (NYSE-MKT: BAS), Energy XXI Ltd. (NASDAQ: EXXI), Key Energy Services, Inc. (NYSE-MKT: KEG) and Magnum Hunter Resources Corp. (NYSE-MKT: MHR) will want to read the following report to gain valuable insight.

An analyst report on BAS, EXXI, KEG, and MHR that includes an industry and company analysis can be viewed by using the following link at no cost.

http://bit.ly/_Energy_Sector_Due_Diligence Copy and paste to browser may be required.

About Broad Street Alerts:
We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement:
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure:
Content is researched, written and reviewed on a best-effort basis by a Michael McCord, Chartered Financial Analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

Contact:
editor@broadstreetalerts.com

SOURCE: Broad Street Alerts

ReleaseID: 431629

FREEHOLD, NJ / ACCESSWIRE / August 31, 2015 / MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would like to update shareholders regarding a major company development. Medifirst Solutions is pleased to announce that its FDA submission for 510(k) approval has been completed and submitted. Medifirst is seeking the approval for a line of affordable, mobile hand-held Laser devices that many different healthcare and medical professionals can use to help patients with specific cosmetic skin conditions as well as relief of muscle and joint pain, muscle spasm and inflammation. Commented President Bruce J. Schoengood, “We are thrilled to have filed the submission after many months of working very closely with our FDA Consulting Group to complete and fine-tune the application and presentation. We consider our Laser devices to be a real game-changer in the industry and we are excited to move forward and on to the next stage of our business plan to roll out a national sales and marketing campaign upon FDA approval. The company is currently building a sales and marketing program for international sales and distributors.”

As recently announced, Medifirst has a wholly-owned subsidiary named Medical Lasers Manufacturer, Inc. The Laser division and related products including treatment programs will be operated out of this subsidiary. Driven by the huge demand for minimally invasive skin and pain treatments, the global market for medical and therapeutic lasers have been estimated to grow as high as to $4 billion in 2015.

About Medifirst Solutions, Inc

Medifirst Solutions, Inc. is a Nevada corporation that is headquartered in New Jersey. The company seeks innovative medical and healthcare products and technologies which are targeted to both medical and healthcare professionals as well as everyday consumers. Medifirst Solutions is developing and establishing both consumer and professional medical cliental that can serve as a pipeline that will allow for distribution of future new products and services. For more details visit www.medifirstsolutions.com for more information.

About Medical Lasers Manufacturer

Medical Lasers Manufacturer will specialize in producing high quality diode-pumped solid-state lasers. We are working with a group of engineers with decades of experience in laser research and manufacturing that have been providing customized laser products to a wide variety of universities and labs. MLM plans to develop new laser products to meet the universal medical needs including new applications which will all adhere to FDA requirements and guidelines. MLM has met all the ISO International Standards to ensure that products and services are safe, reliable and of good quality. All Lasers we bring to market will have EMC, IEC and CE certifications.

Forward-Looking Statements: The statements in this press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements.

Contact:
Investor Relations
Phone: (732) 786-8044
Email: info@medifirstsolutions.com
Website: www.medifirstsolutions.com

SOURCE: Medifirst Solutions, Inc.

ReleaseID: 431631

MELBOURNE, AUSTRALIA / ACCESSWIRE / August 31, 2015 / Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers, today announced that the Company’s Australian patent application covering its lead product PRP was accepted recently by the Australian Patent Office.

The Australian patent application describes a pharmaceutical composition for treating cancer comprising the proenzymes trypsinogen and/or chymotrypsinogen, as well as several other active agents disclosed in the patent.

Importantly, claims directed to compositions, as well as method of treatment claims, were accepted by the Australian Patent Office. This is considered a great result as composition claims are often difficult to patent and are considered more valuable commercially.

Propanc’s lead patent application is now accepted or granted in Australia, New Zealand and South Africa, and under examination in key global regions such as the United States and European Union. The Company expects the recent acceptance in Australia to support ongoing applications in other territories under examination.

Propanc aims to fast track the development of proenzyme related oncology products into clinical trials for colorectal and pancreatic tumors initially. According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by the year 2015.

“The Propanc management team are very pleased with our recent patent acceptance in Australia,” said James Nathanielsz, Propanc’s Chief Executive Officer. “The combined market for pancreatic and colorectal cancers is around ten billion dollars and we believe PRP could make a real difference for patients suffering from these diseases. Establishing a first class intellectual property portfolio is the cornerstone for supporting this vision.”

About Propanc:

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers. Propanc have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc’s products involve or employ proenzymes, which are inactive precursors of enzymes.

In the near term, Propanc intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, Propanc intend to development their lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.

Forward-looking Statements:

Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.

Contact:

Regal Consulting
Tel: 702 – 575 – 9157

SOURCE: Propanc Health Group Corporation

ReleaseID: 431639

REDONDO BEACH, CA / ACCESSWIRE / August 31, 2015 / Diabetes is a large and growing problem in the U.S. and around the world. In the U.S., there are an estimated 21 million diagnosed cases, and an additional eight million undiagnosed cases, of diabetes, according to the Centers for Disease Control. The International Diabetes Foundation currently projects approximately 387 million people worldwide are suffering from the disease, with that figure expected to jump to nearly 600 million by 2035 – just 20 years from now.

While the disease cannot be cured, there are plenty of treatment options that are covered by public healthcare. The IDF estimates that one in nine dollars spent on healthcare worldwide goes towards the treatment of diabetes. That figure is poised to increase significantly over the coming years as diagnostics improve – it’s estimated that only about half of those suffering from diabetes are diagnosed with the disease – and the patient population expands.

Treating Diabetes

Diabetes is a metabolic disease characterized by high blood sugar levels over a prolonged period of time. While the cause of Type 1 diabetes is unknown, Type 2 diabetes occurs when a person acquires insulin resistance due to unhealthy eating and a lack of exercise. The disease has serious long-term complications, including cardiovascular disease, stroke, chronic kidney failure, foot ulcers, eye damage, and many others.

Insulin is a hormone that regulates the uptake of glucose from the blood into the liver, muscle, fat tissue, and other cells throughout the body. In the case of insulin resistance, glucose is not absorbed properly into the body’s cells and isn’t stored properly in the liver or muscles. The net effect is high levels of blood glucose – since it’s not being converted, which can result in poor protein synthesis, and potentially other metabolic issues like acidosis in extreme cases.

The status quo for diabetes treatment is maintaining normal blood sugar levels without causing low blood sugar, as well as boosting insulin levels. In 1922, the first diabetic patient was injected with insulin, and in the early 1950s, the first synthetic insulin injections were developed and given to diabetic patients in order to help control their conditions. The practice has since become the most common treatment for diabetes management.

Insulin Wars

Eli Lilly & Co. (NYSE: LLY) and Genentech – now owned by Roche Holdings Ltd. (OTC: RHHBY) – were the first two companies to begin selling injectable insulin in the 1970s. Since then, a number of companies have entered the market and commoditized the substance, although insulin injections still cost around $400 per month. These costs could come down – as with most generic drugs – but likely on a much smaller scale than pharmaceuticals.

Most of the innovation occurring within the diabetes space is aimed at making insulin injections easier, rather than trying to cure diabetes or eliminate insulin requirements altogether. For instance, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is developing an ingestible insulin capsule that’s in Phase II clinical trials, while MannKind Corporation’s (NASDAQ: MNKD) Afrezza is an inhalable form of insulin that avoids shots and pills.

Many other companies are working on treating the complications of diabetes, including conditions like diabetic neuropathy or foot ulcers that can lead to amputations. For instance, NephroGenex (NASDAQ: NRX) recently raised $7.5 million to complete the Phase III clinical trial of Pyridorin – a drug developed to treat diabetic neuropathy. The drug reportedly works by blocking the formation of chemical compounds that contribute to kidney damage.

New Approaches

Cell MedX Corp. (OTC: CMXC) is taking a radically different approach to diabetes treatment that could create an entire new category in the space. Last year, the company acquired the rights to a proprietary microcurrent technology – called eBalance – that is being developed to improve key diabetic metabolic markers and reduce the need for insulin, while improving the long-term prognosis for the growing number afflicted with the condition.

The eBalance device is expected to be an easy-to-use, iPad-sized homecare device that may only require short 10 to 20 minute treatments a few times per week. Management believes that the proposed approach utilizing a simple, patient-friendly, non-invasive, and pain-free technology will make it appealing to diabetics that have been suffering through ongoing and sometimes painful treatments for years.

Co-founder Jean Arnett has become patient zero for the technology, having lived with Type 1 diabetes for over 40 years. Using eBalance, she reported A1C levels that fell from 10.7 to 7.5, a decrease of more than 50% in her 24 hour basal rate insulin, and short term insulin sensitivity that increased 60%, as well as ancillary benefits, including lower blood pressure, improved kidney function, abatement of all diabetic neuropathy, and faster-healing diabetic wounds. Moreover, these benefits were realized without any side effects.

As a result of Ms. Arnett’s personal success, the company started recruiting 30 Type 1 and 2 diabetic patients for a Phase II-A clinical trial to be conducted in Orange County, California this year. Over the upcoming months, the company’s medical team will carefully study clinical endpoints, including the reduction of HbA1C levels independent of other factors. The trials will also take a look at how metabolic changes and pathways lead to improved glycemic control and what settings are optimal for the technology. If the results warrant, the Company aims to move ahead with additional trials aimed at the development of a commercial device as part of their overall business strategy.

Looking Ahead

Diabetes is a massive and growing problem at a global scale, while few companies are working on breakthrough changes to contain costs. Unlike many other investment opportunities in the space, Cell MedX is working to develop a potentially low-cost technology that could dramatically improve patient outcomes. The win-win nature of its innovative solution could take a big slice of a multi-billion dollar market that’s in desperate need of safe and efficacious treatments.

For more information, visit the company’s website at www.cellmedx.com.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

SOURCE: Emerging Growth LLC

ReleaseID: 431608